According to experts, the danger from the coronavirus SARS-CoV-2 can be averted if a vaccination against the novel pathogen is available. Scientists around the world are working on vaccines. Now one of them is being tested on humans in Germany.
A few weeks ago, the University Medical Center Hamburg-Eppendorf (UKE) received approval to start clinical testing of a vaccine against COVID-19. Now the first study participants have been vaccinated against the coronavirus SARS-CoV-2.
According to a recent announcement, last Friday, October 9, the first volunteer was injected with the vaccine MVA-SARS-2-S against COVID-19. According to the information, a total of six test persons have been administered the vector vaccine so far.
Clinical trial started
At the end of September, the University Medical Center Hamburg-Eppendorf (UKE) received approval from the Paul Ehrlich Institute, Federal Institute for Vaccines and Biomedical Drugs, and the Ethics Commission of the Hamburg Medical Association to start clinical trials of the vaccine.
The vaccine was developed by scientists of the German Centre for Infection Research (DZIF) and IDT Biologika GmbH and is now being tested in clinical Phase I for safety, tolerability and specific immune response against the new pathogen.
Preliminary investigations and the selection of healthy volunteers were started in early October, before the vaccination of the first volunteer on October 9th. With the necessary safety margin, the vaccination of further subjects followed. “So far, everything has gone according to plan and as expected,” explains Prof. Marylyn Addo, Head of Infectiology at the UKE, who is the investigator in charge of the clinical trial.
According to the information provided, the total of 30 test persons aged 18 to 55 years will be vaccinated in eight groups and in two ascending doses. The study participants will receive two vaccinations at four-week intervals and will be monitored for a few hours after each vaccination at CTC North, the UKE’s contract medical center.
The scientists in the research group of Prof. Addo and the DZIF partners in Marburg measure the production of antibodies and T-cells in the body in parallel and compare this with the immune response of recovered COVID-19 patients. (ad)
On the days following the vaccinations and for the following six months, participants must come for regular follow-up outpatient examinations to check the tolerability of the vaccine, possible side effects and the immune response by means of blood tests and interviews.
Vaccine against COVID-19 being tested
WashingtonNewsday Health and Wellness.